文献速递血栓与止血

胎儿和新生儿同种免疫性血小板减少症患儿的产后治疗:一项多中心、回顾性、队列研究

Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study.
PubMed 文献 · Lancet Haematol · 2022-09-12

该多中心回顾性队列研究纳入7个国家8个中心的389例胎儿和新生儿同种免疫性血小板减少症(FNAIT)活产新生儿,描述产后治疗与结局;42%未接受产后治疗,53%接受血小板输注,28%接受静脉注射免疫球蛋白,各国HPA匹配输注比例差异大(0%至63%);HPA匹配输注后血小板增量中位数高于未匹配输注。

要点

  • FNAIT新生儿产后管理在国际中心间差异很大,缺乏最佳治疗共识。
  • HPA匹配血小板输注后血小板增量中位数高于HPA未匹配输注。
  • HPA匹配是否与出血风险降低相关仍未知。

核心结论

  • FNAIT的产后管理在国际中心间差异很大,凸显缺乏最佳治疗的共识。
  • 数据提示HPA匹配输注比HPA未匹配输注带来更大的中位血小板计数增量,但HPA匹配是否也与出血风险降低相关仍未知。

研究设计与样本

  • 多中心、回顾性、队列研究,建立基于网络的注册登记收集FNAIT新生儿管理和病程的去标识化数据。
  • 7个国家(澳大利亚、挪威、斯洛文尼亚、西班牙、瑞典、荷兰和美国)的8个中心参与。
  • 纳入2010年1月1日至2020年1月1日间活产、母血清存在抗人血小板抗原(HPA)同种抗体、确认母胎HPA不合,且当前或既往妊娠产前超声发现出血和(或)新生儿血小板减少(<150×10^9/L)的新生儿。
  • 408例FNAIT活产新生儿进入FNAIT注册登记,其中389例纳入分析(澳大利亚n=74、挪威n=56、斯洛文尼亚n=19、西班牙n=55、瑞典n=31、荷兰n=138、美国n=16)。
  • 中位随访5天(IQR 2-9)。

主要发现

  • 男性241例(64%)多于女性138例(36%)(男性/女性分别占379例中的241例和138例)。
  • 严重血小板减少(血小板计数<50×10^9/L)报告于283例(74%)/380例新生儿,极重度血小板减少(<10×10^9/L)报告于92例(24%)新生儿。
  • 无治疗组产后血小板计数最低值高于所有其他组。
  • 389例FNAIT新生儿中163例(42%)未接受产后治疗;207例(53%)接受血小板输注,其中HPA未匹配88例(43%)、HPA匹配84例(41%)、两者联合35例(17%)。
  • 接受HPA匹配血小板输注的新生儿比例各国间从0%(斯洛文尼亚)到63%(挪威,35/56例)不等;产后静脉注射免疫球蛋白治疗110例(28%)/389例(单用n=19,联合血小板输注n=91),各国间从12%(荷兰,17/138例)到63%(美国,10/16例)不等。

临床怎么用

  • 原文未据此给出推荐。
  • 作者指出数据提示HPA匹配输注比HPA未匹配输注带来更大的中位血小板计数增量,但HPA匹配是否也与出血风险降低相关仍未知。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) are at risk of severe intracranial haemorrhage. Management in the postnatal period is based on sparse evidence. We aimed to describe the contemporary management and outcomes of patients with FNAIT in high-income countries. METHODS: In this multicentre, retrospective, cohort study, we set up a web-based registry for the collection of deidentified data on the management and course of neonates with FNAIT. Eight centres from seven countries (Australia, Norway, Slovenia, Spain, Sweden, the Netherlands, and the USA) participated. Eligibility criteria comprised neonates with FNAIT being liveborn between Jan 1, 2010, and Jan 1, 2020; anti-human platelet antigen (HPA) alloantibodies in maternal serum; confirmed maternal and fetal HPA incompatibility; and bleeding detected at antenatal ultrasound, neonatal thrombocytopenia (<150 × 109 platelets per L), or both in the current or previous pregnancy. Clinical data were retrieved from local medical records of the first neonatal admission and entered in the registry. The key outcome was the type of postnatal treatment given to neonates with FNAIT. Other outcomes were daily median platelet counts in the first week of life, median platelet count increment after first unmatched versus first matched transfusions, and the proportion of neonates with mild or severe bleeding. FINDINGS: 408 liveborn neonates with FNAIT were entered into the FNAIT registry, of whom 389 from Australia (n=74), Norway (n=56), Slovenia (n=19), Spain (n=55), Sweden (n=31), the Netherlands (n=138), and the USA (n=16) were included in our analyses. The median follow-up was 5 days (IQR 2-9). More neonates were male (241 [64%] of 379) than female (138 [36%]). Severe thrombocytopenia (platelet count <50 × 109 platelets per L) was reported in 283 (74%) of 380 neonates, and extreme thrombocytopenia (<10 × 109 platelets per L) was reported in 92 (24%) neonates. Postnatal platelet count nadir was higher in the no-treatment group than in all other groups. 163 (42%) of 389 neonates with FNAIT received no postnatal treatment. 207 (53%) neonates received platelet transfusions, which were either HPA-unmatched (88 [43%] of 207), HPA-matched (84 [41%]), or a combination of both (35 [17%]). The proportion of neonates who received HPA-matched platelet transfusions varied between countries, ranging from 0% (Slovenia) to 63% (35 of 56 neonates; Norway). Postnatal intravenous immunoglobulin treatment was given to 110 (28%) of 389 neonates (alone [n=19] or in combination with platelet transfusions [n=91]), with the proportion receiving it ranging from 12% (17 of 138 neonates; the Netherlands) to 63% (ten of 16 neonates; the USA) across countries. The median platelet increment was 59 × 109 platelets per L (IQR 35-94) after HPA-unmatched platelet transfusions and 98 × 109 platelets per L (67-134) after HPA-matched platelet transfusions (p<0·0001). Severe bleeding was diagnosed in 23 (6%) of 389 liveborn neonates, with one having a severe pulmonary haemorrhage and 22 having severe intracranial haemorrhages. Mild bleeding was diagnosed in 186 (48%) neonates. INTERPRETATION: Postnatal management of FNAIT varies greatly between international centres, highlighting the absence of consensus on optimal treatments. Our data suggest that HPA-matched transfusions lead to a larger median platelet count increment than HPA-unmatched transfusions, but whether HPA matching is also associated with a reduced risk of bleeding remains unknown. FUNDING: Sanquin.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. de Vos TW, Winkelhorst D, Árnadóttir V, et al. Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study. Lancet Haematol. 2022. PMID: 36108655. doi:10.1016/S2352-3026(22)00243-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。